Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Invesco Ltd. — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Invesco Ltd. trades at $27.87 (market cap $12.77B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.97% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Invesco Ltd. for 77 Days on average.
| HNGE | IVZ | |
|---|---|---|
Market Cap | $8.48B | $12.77B |
Volume | 879,799 | 2,758,656 |
Sector | Health | Financials |
52-Week High | $105.14 | $33.31 |
52-Week Low | $31.17 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $8.10B | $22.93B |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Invesco (IVZ) trades at $27.93, down 4.55% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, with a negative net income margin of -0.93%. Recent news highlights product expansions, including the launch of the Invesco Nasdaq International Innovators 100 ETF, and a dividend of $0.22 per share scheduled for September 2026.
The outlook is cautious; analyst consensus is a buy with a $33.17 price target, but profitability challenges and bearish technicals pose risks. Positive cash flow and AUM growth offer potential, yet investors must weigh weak margins against strategic initiatives in a competitive ETF landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
